作者
Hagop Kantarjian,Anthony S. Stein,Nicola Gökbuget,Adele K. Fielding,Andre C. Schuh,Josep‐María Ribera,Andrew H. Wei,Hervé Dombret,Robin Foà,Renato Bassan,Önder Arslan,Miguel Á. Sanz,Julie Bergeron,Fatih Demırkan,Ewa Lech‐Marańda,Alessandro Rambaldi,Xavier Thomas,Heinz-August Horst,Monika Brüggemann,Wolfram Klapper,Brent L. Wood,A. Fleishman,Dirk Nagorsen,Christopher P. Holland,Zachary Zimmerman,Max S. Topp
摘要
Blinatumomab, a bispecific monoclonal antibody construct that enables CD3-positive T cells to recognize and eliminate CD19-positive acute lymphoblastic leukemia (ALL) blasts, was approved for use in patients with relapsed or refractory B-cell precursor ALL on the basis of single-group trials that showed efficacy and manageable toxic effects.